公开(公告)号：US11919960B2

公开(公告)日：2024-03-05

申请号：US16979933

申请日：2019-03-13

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Sergio Quezada

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07K14/55 ,  C12N15/85

CPC classification number: C07K16/2866 ,  A61K39/39533 ,  A61K39/39541 ,  A61K39/39558 ,  A61K39/39566 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07K14/55 ,  C07K16/2818 ,  C07K16/2827 ,  C12N15/85 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/32 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2015/8518

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in 5 pharmaceutical compositions and methods of treatment, in particular for treating cancer.

公开(公告)号：US11802161B2

公开(公告)日：2023-10-31

申请号：US16979929

申请日：2019-03-13

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Mark Brown ,  James Geoghegan ,  Bianka Prinz ,  Sergio Quezada

IPC: C07K16/28 ,  A61P35/02 ,  C12N15/85 ,  A61P35/00 ,  A61K39/395 ,  C07K14/55 ,  A61K45/06 ,  A61K39/00

CPC classification number: C07K16/2866 ,  A61K39/39533 ,  A61K39/39541 ,  A61K39/39558 ,  A61K39/39566 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07K14/55 ,  C07K16/2818 ,  C07K16/2827 ,  C12N15/85 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/32 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2015/8518

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-634 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.

公开(公告)号：US11787866B2

公开(公告)日：2023-10-17

申请号：US16782461

申请日：2020-02-05

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Mark Brown ,  Sergio Quezada ,  James Geoghegan ,  Bianka Prinz

IPC: C07K16/28 ,  A61P35/02 ,  A61P35/00 ,  A61K39/395 ,  C07K14/55 ,  A61K45/06 ,  A61K39/00 ,  C12N15/85

CPC classification number: C07K16/2866 ,  A61K39/39533 ,  A61K39/39541 ,  A61K39/39558 ,  A61K39/39566 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07K14/55 ,  C07K16/2818 ,  C07K16/2827 ,  C12N15/85 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/32 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2015/8518

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

公开(公告)号：US20220241333A1

公开(公告)日：2022-08-04

申请号：US17622190

申请日：2020-07-03

Applicant: Cancer Research Technology Limited ,  University College London

Inventor： Sergio Quezada ,  Karl Peggs ,  Anna Sledzinska ,  Richard Jenner ,  Felipe Galvez Cancino ,  Maria Vila de Mucha

IPC: A61K35/17 ,  A61P35/00 ,  C07K14/725 ,  C12N15/10

Abstract: The present invention provides an engineered T cell for use in a method of treatment of a proliferative disorder in a mammalian subject, wherein the T cell has been engineered (i) to overexpress BLIMP1 and/or (ii) to knock-out or decrease expression of BCL6. Further provided is a BCL6 inhibitor for use in a method of enhancing immunotherapy in a subject having a proliferative disorder. Also provided are related methods of treatment employing the engineered T cell and/or BCL6 inhibitor.

公开(公告)号：US10738125B2

公开(公告)日：2020-08-11

申请号：US16352703

申请日：2019-03-13

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Mark Brown ,  Sergio Quezada ,  James Geoghegan ,  Bianka Prinz

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K39/00 ,  A61P35/02 ,  C07K14/55 ,  C12N15/85

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

公开(公告)号：US20230158073A1

公开(公告)日：2023-05-25

申请号：US17919135

申请日：2021-04-16

Applicant: Cancer Research Technology Limited

Inventor： Sergio Quezada ,  Karl Peggs ,  Charles Swanton ,  Ehsan Ghorani ,  James Reading ,  Felipe Galvez-Cancino ,  Despoina Karagianni

IPC: A61K35/17 ,  A61K38/17 ,  A61P35/00

CPC classification number: A61K35/17 ,  A61K38/1774 ,  A61P35/00

Abstract: The present invention provides an engineered T cell for use in a method of treatment of a proliferative disorder, wherein the engineered T cell has modulated expression of one or more genes selected from SIT1, SAMSN1, SIRPG, CD7, CD82, FCRL3, IL1RAP, FURIN, STOM, AXL, E2F1, C5ORF30, CLDND1, COTL1, DUSP4, EPHA1, FABP5, GFI1, ITM2A, PARK7, PECAM1, PHLDA1, RAB27A, RBPJ, RGS1, RGS2, RNASEH2A, SUV39H1, and TNIP3. Further provided are activity modulators of one or more proteins encoded by genes selected from SIT1, SAMSN1, SIRPG, CD7, CD82, FCRL3, IL1RAP, FURIN, STOM, AXL, E2F1, C5ORF30, CLDND1, COTL1, DUSP4, EPHA1, FABP5, GFI1, ITM2A, PARK7, PECAM1, PHLDA1, RAB27A, RBPJ, RGS1, RGS2, RNASEH2A, SUV39H1, and TNIP3 for use in a method of enhancing immunotherapy in a subject having a proliferative disorder. Also provided are related methods of treatment employing the engineered T cell and/or inhibitor.

公开(公告)号：US20210009702A1

公开(公告)日：2021-01-14

申请号：US16979929

申请日：2019-03-13

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Mark Brown ,  James Geoghegan ,  Bianka Prinz ,  Sergio Quezada

IPC: C07K16/28

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-634 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.

公开(公告)号：US20210009699A1

公开(公告)日：2021-01-14

申请号：US16782461

申请日：2020-02-05

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Mark Brown ,  Sergio Quezada ,  James Geoghegan ,  Bianka Prinz

IPC: C07K16/28 ,  A61P35/02 ,  C12N15/85 ,  A61P35/00 ,  A61K39/395 ,  C07K14/55

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

公开(公告)号：US20180251553A1

公开(公告)日：2018-09-06

申请号：US15758165

申请日：2016-09-12

Applicant: CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Nicholas McGranahan ,  Rachel Rosenthal ,  Charles Swanton ,  Karl Peggs ,  Sergio Quezada

IPC: C07K16/28 ,  G06F19/22 ,  G06F19/24 ,  G01N33/574

CPC classification number: C07K16/2818 ,  C07K2317/24 ,  C07K2317/76 ,  G01N33/574 ,  G01N33/57411 ,  G16B30/00 ,  G16B40/00

Abstract: The present invention relates to methods for identifying a subject with cancer who is suitable for treatment with an immune checkpoint intervention, and to methods of treatment of such subjects. The invention further relates to a method for predicting or determining the prognosis of a subject with cancer.

公开(公告)号：US11873341B2

公开(公告)日：2024-01-16

申请号：US16979932

申请日：2019-03-13

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Sergio Quezada

IPC: C07K16/28 ,  A61P35/02 ,  C12N15/85 ,  A61P35/00 ,  A61K39/395 ,  C07K14/55 ,  A61K45/06 ,  A61K39/00 ,  C07K14/05

CPC classification number: C07K16/2866 ,  A61K39/39533 ,  A61K39/39541 ,  A61K39/39558 ,  A61K39/39566 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07K14/05 ,  C07K16/2818 ,  C07K16/2827 ,  C12N15/85 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/32 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2015/8518

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-674 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: YQCVQGYRALHRGP (150 to 163) or SVCKMTHGKTRWTQP (166 to 180) on CD25 Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.